Expression of Soluble c-Met in the serum and peritoneal fluid of the patients with different stages of Endometrial Cancer
Session type: Poster / e-Poster / Silent Theatre session
Theme: Diagnosis and therapy
Hepatocyte growth factor (HGF) which is also known as scattering factor (SF), and its receptor c-Met were shown to be important in endometrial cancer. HGF plays as a mitogen, motogen, and morphogen on endometrial epithelial cells. The expression of c-Met on human endometrial cells has been reported. Many integral membrane proteins including c-Met has been shown to be proteolytically released from the surface by a process known as ectodomain shedding to form soluble, truncated proteins. The soluble receptors are smaller, consisting of the extracellular origin of the membrane-bound receptor and, in general, are able to bind to ligand with reduced affinity. We hypothesized that HGF:c-Met signaling may be important to the pathophysiology of endometrial carcinoma (EC). In this study we measured the expression of soluble c-Met in the serum and peritoneal fluid of patients with EC and compared to controls.
49 peritoneal fluid (PF) and serum samples from normal healthy and 58 samples from EC were included in this study. Soluble cMet in serum and PF was measured using the sensitive two sided enzyme linked immunosorbent assay (ELISA) and western blotting.
The present study demonstrated that the concentration of soluble c-Met in serum and PF of women with EC increased as compared to controls (P=0.002). Moreover, a high expression of soluble c-Met in serum and PF is correlated with advanced stages of EC.
In conclusion the results of this study demonstrate that HGF/c-Met system may be involved in the pathogenesis of EC. It is also suggested that a high expression of soluble c-Met is correlated with advanced stages of EC. Therefore, the detection of serum soluble c-Met may be useful in classifying EC.